IFNB1 and neoplasm: Here, we are taking advantage of the dose-dependent IFNβ effect; a first round of stimulation and thereby low IFNβ levels barely impact CAR T-cell survival and anti-tumor activity, while repetitive rounds increase IFNβ release to levels that induce CAR T-cell apoptosis.